search
Back to results

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Primary Purpose

Renal Artery Stenosis

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Gadoterate meglumine (Dotarem)
Time of Flight Magnetic Resonance Angiography
Sponsored by
Guerbet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Renal Artery Stenosis focused on measuring Renal artery stenosis, Contrast agent, MRA

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, aged more than 18 years,
  • Strongly suspected of having renal arterial disease,
  • Scheduled (or to be scheduled) to undergo arterial catheter-based X-ray angiography examination,

Exclusion Criteria:

  • Known grade IV or V chronic kidney disease (GFR<30 mL/min/1.73m²),
  • Contraindication to MRI,
  • Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination,

Sites / Locations

  • Guerbet LLC

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Dotarem

Time Of Flight Magnetic Resonance Angiography

Arm Description

Each subject will receive one injection of Dotarem 0.2 ml/kg.

Each subject undergo a TOF MRA

Outcomes

Primary Outcome Measures

Percent of Non Assessable Renal Artery Segments
For each examination (TOF and Dotarem MRA) the percent of non-assessable segment will be compared

Secondary Outcome Measures

Full Information

First Posted
February 16, 2009
Last Updated
April 19, 2016
Sponsor
Guerbet
search

1. Study Identification

Unique Protocol Identification Number
NCT00845702
Brief Title
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Official Title
Evaluation of Dotarem-enhanced Magnetic Resonance Angiography (MRA) Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Renal Arterial Disease
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Terminated
Why Stopped
lack of recruitment.
Study Start Date
April 2009 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Guerbet

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.
Detailed Description
Each participant will undergo first a TOF MRA followed by a Dotarem-enhanced MRA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Artery Stenosis
Keywords
Renal artery stenosis, Contrast agent, MRA

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dotarem
Arm Type
Experimental
Arm Description
Each subject will receive one injection of Dotarem 0.2 ml/kg.
Arm Title
Time Of Flight Magnetic Resonance Angiography
Arm Type
Other
Arm Description
Each subject undergo a TOF MRA
Intervention Type
Drug
Intervention Name(s)
Gadoterate meglumine (Dotarem)
Intervention Description
Each subject will receive one injection of Dotarem 0.2 ml/kg
Intervention Type
Other
Intervention Name(s)
Time of Flight Magnetic Resonance Angiography
Intervention Description
Each subject will undergo a TOF MRA
Primary Outcome Measure Information:
Title
Percent of Non Assessable Renal Artery Segments
Description
For each examination (TOF and Dotarem MRA) the percent of non-assessable segment will be compared
Time Frame
1 to 7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, aged more than 18 years, Strongly suspected of having renal arterial disease, Scheduled (or to be scheduled) to undergo arterial catheter-based X-ray angiography examination, Exclusion Criteria: Known grade IV or V chronic kidney disease (GFR<30 mL/min/1.73m²), Contraindication to MRI, Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination,
Facility Information:
Facility Name
Guerbet LLC
City
Bloomington
State/Province
Indiana
ZIP/Postal Code
47403
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

We'll reach out to this number within 24 hrs